A partnership between OraSure Technologies (Bethlehem, Pennsylvania) and AbbVie (North Chicago) could put testing individuals at-risk for hepatitis C (HCV) in the forefront of testing for the disease. OraSure held an investor call Wednesday morning to discuss details of the agreement, under which the company and AbbVie will co-promote its OraQuick HCV rapid test in the U.S. Read More
